StudyFinder

A RANDOMIZED PHASE III STUDY OF IBRUTINIB PLUS OBINUTUZUMAB VERSUS IBRUTINIB PLUS VENETOCLAX AND OBINUTUZUMAB IN UNTREATED OLDER PATIENTS (≥ 70 YEARS OF AGE) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Recruiting
I'm interested

This study is NOT accepting healthy volunteers

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Ava Athmann - ava.athmann@parknicollet.com
Birendra Kumar
Phase III
0123456789
NCT03737981
See this study on ClinicalTrials.gov

Back